JNJ-88545223 for Psoriatic Arthritis

(VELOTA Trial)

Recruiting at 3 trial locations

Overseen By Study Contact

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Janssen Research & Development, LLC

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

240 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.

Who Is on the Research Team?

Janssen Research & Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Are You a Good Fit for This Trial?

This trial is for adults with active Psoriatic Arthritis (PsA) diagnosed at least 3 months prior, meeting specific criteria including having at least 3 swollen and tender joints, elevated CRP levels, and certain types of arthritis or skin/nail psoriasis. Women must test negative for pregnancy.

Inclusion Criteria

I have been diagnosed with psoriatic arthritis for at least 3 months.

I have PsA with at least 3 swollen and 3 tender joints and a CRP level of >=0.1 mg/dL.

I have PsA affecting my fingers, many joints, or spine with arthritis.

What Are the Treatments Tested in This Trial?

Interventions

• JNJ-88545223

Trial Overview

The study tests the effectiveness and safety of JNJ-88545223 compared to a placebo in reducing symptoms of PsA. It aims to improve joint and skin health by assessing changes after administering the study drug or an inactive substance.

How Is the Trial Designed?

Group I: Arm 4: JNJ-88545223 Dose 3 Experimental Treatment 1 Intervention

Participants will receive JNJ-88545223 Dose 3 from Week 0 to Week 16.

Group II: Arm 3: JNJ-88545223 Dose 2 Experimental Treatment 1 Intervention

Participants will receive JNJ-88545223 Dose 2 from Week 0 to Week 16.

Group III: Arm 2: JNJ-88545223 Dose 1 Experimental Treatment 1 Intervention

Participants will receive JNJ-88545223 Dose 1 from Week 0 to Week 16.

Group IV: Arm 1: Placebo Placebo Group 1 Intervention

Participants will receive matching placebo to JNJ-88545223, from Week 0 to Week 16.

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials

1,022

Recruited

6,408,000+

Joaquin Duato

Janssen Research & Development, LLC

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD

Janssen Research & Development, LLC

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University